Generalized-onset seizures (GOS) simultaneously affect both sides of the brain and rapidly engage bilaterally distributed networks. Nearly 40% of the diagnosed epilepsy population presents with…
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…
Eosinophilic esophagitis (EoE) is a chronic, allergic inflammatory disease of the esophagus, characterized by an accumulation of eosinophils. It can cause difficulty with swallowing food and has…
The treatment of rheumatoid arthritis (RA) typically begins with cost-effective conventional DMARDs (cDMARDs), such as methotrexate or hydroxychloroquine. For patients who fail cDMARD treatment or…
Long-acting beta2 agonist (LABA) / long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) have been gaining traction in the chronic obstructive pulmonary disease (COPD) market,…
Renal anemia is a common complication of chronic kidney disease (CKD). Although treatments—such as iron therapies, erythropoiesis-stimulating agents (ESAs), and HIF-PH inhibitors—are available…
Treatment of psoriatic arthritis (PsA) typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S…
The rising rates of antimicrobial resistance (AMR) have created an emergent need for development and discovery of antibiotics with activity against drug-resistant gram-negative pathogens (GNPs)…
Attention-deficit/hyperactivity disorder (ADHD) is one of most common pediatric disorders and one that can continue into adulthood. For decades, pediatric ADHD has been treated primarily with…
The launch of several novel therapies and multiple label expansions for premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) / chronic lymphocytic leukemia (CLL…
The ovarian cancer treatment landscape has been transformed by the angiogenesis inhibitor bevacizumab and the poly ADP ribose polymerase (PARP) inhibitors Lynparza (AstraZeneca / Merck & Co.),…
Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum. Treatment typically begins with conventional agents (e.g., 5-aminosalicylic acids [5-ASAs])…
The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics / targeted oral therapies and grow steadily over the next 10 years. The well-established TNF-α inhibitors (…
Myasthenia gravis (MG) is a rare neuromuscular disorder caused by specific autoantibodies at the neuromuscular junction targeting—in most patients—acetylcholine receptors. It is characterized…
Approximately 80% of rare diseases have a genetic etiology. Gene therapies have the potential to transform the treatment of rare diseases and, in some cases, provide a functional cure. However,…